![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCDC170 |
Gene summary for CCDC170 |
![]() |
Gene information | Species | Human | Gene symbol | CCDC170 | Gene ID | 80129 |
Gene name | coiled-coil domain containing 170 | |
Gene Alias | C6orf97 | |
Cytomap | 6q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8IYT3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80129 | CCDC170 | HCC2_Meng | Human | Liver | HCC | 2.39e-03 | 3.67e-02 | 0.0107 |
80129 | CCDC170 | HCC1 | Human | Liver | HCC | 6.31e-22 | 4.37e+00 | 0.5336 |
80129 | CCDC170 | HCC2 | Human | Liver | HCC | 3.91e-14 | 1.41e+00 | 0.5341 |
80129 | CCDC170 | HCC5 | Human | Liver | HCC | 3.79e-21 | 2.82e+00 | 0.4932 |
80129 | CCDC170 | S014 | Human | Liver | HCC | 2.09e-06 | 2.30e-01 | 0.2254 |
80129 | CCDC170 | S015 | Human | Liver | HCC | 2.71e-07 | 2.59e-01 | 0.2375 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | ![]() |
Lung | IAC | ![]() |
Lung | AIS | ![]() |
Lung | AAH | ![]() |
Lung | MIAC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC170 | SNV | Missense_Mutation | c.1177A>G | p.Arg393Gly | p.R393G | Q8IYT3 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC170 | SNV | Missense_Mutation | c.227N>T | p.Ser76Phe | p.S76F | Q8IYT3 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
CCDC170 | SNV | Missense_Mutation | c.1240N>C | p.Glu414Gln | p.E414Q | Q8IYT3 | protein_coding | deleterious(0.04) | possibly_damaging(0.587) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
CCDC170 | SNV | Missense_Mutation | rs780550074 | c.94N>T | p.Arg32Trp | p.R32W | Q8IYT3 | protein_coding | deleterious(0.04) | benign(0.025) | TCGA-E9-A5FK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
CCDC170 | SNV | Missense_Mutation | rs201558474 | c.382G>A | p.Ala128Thr | p.A128T | Q8IYT3 | protein_coding | tolerated(0.71) | benign(0.015) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCDC170 | SNV | Missense_Mutation | c.1912N>C | p.Lys638Gln | p.K638Q | Q8IYT3 | protein_coding | tolerated(0.15) | benign(0.108) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CCDC170 | SNV | Missense_Mutation | rs376388158 | c.494N>A | p.Cys165Tyr | p.C165Y | Q8IYT3 | protein_coding | tolerated(0.3) | benign(0.423) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CCDC170 | SNV | Missense_Mutation | c.593N>A | p.Arg198Lys | p.R198K | Q8IYT3 | protein_coding | tolerated(0.64) | benign(0.005) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CCDC170 | SNV | Missense_Mutation | c.1728N>T | p.Gln576His | p.Q576H | Q8IYT3 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CCDC170 | SNV | Missense_Mutation | c.784N>G | p.Ser262Gly | p.S262G | Q8IYT3 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |